The Biocatalysis Market: Four Estimates, One Decision

Ask five research houses how big biocatalysis is and you get answers that differ by a factor of forty. That spread is not noise. It tells you exactly which definition your business plan has to pick before an investor will read past the first page.

At the narrow end, the market for engineered enzymes and biocatalyst services sold into chemical synthesis is counted in hundreds of millions of dollars. Future Market Insights, 2025 puts biocatalysis and biocatalysts at roughly $739.3 million in 2025, rising to about $1.37 billion by 2035 (a 6.4% compound annual rate). Precedence Research, 2025 lands at about $642 million for the same year and a little over $1.2 billion by 2035. IMARC Group, 2025 sizes the biocatalyst market at about $626 million.

At the wide end, Market Research Future, 2025 projects the biocatalysis and biocatalysts industry at about $27.9 billion in 2025, a figure that folds in the huge bulk enzyme volumes sold into detergents, food processing, animal feed and biofuels.

Which number belongs in your plan

If you sell enzyme engineering, screening panels or process development to pharmaceutical and fine-chemical manufacturers, your serviceable market is the narrow $0.6B to $0.75B pool. Quote that one. If you plan to manufacture a commodity enzyme for detergents or feed, you are competing for a slice of the broad pool, against Novonesis (the company formed when Novozymes and Chr. Hansen combined) and a handful of similar-scale producers with decades of fermentation capacity. Lenders who know the sector will mark down a plan that cites $27.9B while describing a four-person screening lab.

A defensible market section does three things. It names the definition (pharma and fine-chemical biocatalysis, not all enzymes). It shows the arithmetic from the market to your realistic share, for example 0.05% of a $700 million pool is $350,000 of annual revenue, which is a credible year-two number for a specialist service lab. It then explains what grows the pool: pharmaceutical manufacturers replacing metal-catalysed steps with enzymatic ones, oligonucleotide and peptide therapeutics needing new synthesis routes, and corporate waste and energy targets that favour reactions run at room temperature in water.

Where the demand actually comes from

• Small-molecule pharmaceutical manufacturing. Chiral amines, alcohols and acids where a single mirror-image form is required. Enzymes deliver selectivity that metal catalysts need expensive ligands to approximate.
• Oligonucleotide and RNA therapeutics. Enzymatic synthesis is being developed as an alternative to solid-phase chemistry. Codexis describes its ECO Synthesis platform as having "well over 30" opportunities in various stages of maturation and reported its first revenue-generating manufacturing contract in early 2025 (see the Codexis FY2025 Form 10-K).
• Flavours, fragrances and food ingredients. Natural-label positioning favours enzymatic routes, but food-use enzymes bring their own approval path (covered in the regulation section below).
• Specialty and fine chemicals. Surfactants, polymers precursors and agrochemical intermediates, where volumes are smaller than commodity chemicals and per-kilogram prices tolerate biocatalyst costs.
• Bio-based fuels and materials. The largest volumes but the thinnest margins. A startup rarely wins here without a proprietary enzyme that cuts a specific cost line.

The US Department of Energy has published a biocatalysis technology roadmap arguing that new biocatalysts are essential tools for sustainable chemical manufacturing. It is a useful citation for the strategic rationale section of a grant application, though it predates the current generation of machine-learning-guided enzyme design, so pair it with recent commercial evidence.

What Commercial Biocatalysis Has Already Proven

Investors in this sector ask one question before any other: has an enzyme ever displaced a chemical step at manufacturing scale, and did anyone make money? The answer is yes, and the named examples are the strongest evidence you can put in a plan.

Sitagliptin: the reference case

Merck and Codexis replaced a rhodium-catalysed hydrogenation in the manufacture of sitagliptin, the active ingredient in the diabetes drug Januvia, with an engineered transaminase. The evolved enzyme showed a compounded activity improvement of more than 25,000-fold over the starting enzyme, produced no detectable amount of the unwanted mirror-image form, and raised overall yield by 10 to 13 percent while cutting waste. The two companies received the 2010 Presidential Green Chemistry Challenge Award from the US EPA for the route. Codexis later signed a multi-year supply extension with Merck for the enzyme, reported by Fierce Pharma.

For your plan, the lesson is the commercial structure, not the chemistry. The enzyme developer keeps supplying the catalyst for the life of the drug. That recurring supply revenue is what turns a one-off engineering fee into an annuity, and it is the pattern a lender wants to see you pursuing.

Codexis at scale

Codexis reported total revenue of $70.4 million for the fiscal year ended 31 December 2025, with strong performance in its pharma biocatalysis business, per its fourth-quarter 2025 results release. As of that date the company sold enzymes into the manufacture of 18 approved therapeutic drugs. Use this as a ceiling comparable: a company with two decades of platform work and a listed balance sheet sits at roughly $70 million a year. A startup plan that forecasts $20 million in year three is not credible, and reviewers will say so.

Service-led players and where they sit

• Almac (Northern Ireland) committed a reported $4 million to expand its biocatalysis group, covering new platforms, lower enzyme loadings and cofactor recycling, according to C&EN. A contract-research and manufacturing business built around enzyme services.
• Johnson Matthey bought X-Zyme in July 2010 and folded biocatalyst products and services into its catalysis and chiral technologies unit. Evidence that a large chemical catalyst company prefers to acquire enzyme capability, which matters for your exit section.
• Enzymaster markets AI-guided enzyme discovery and engineering through its BioEngine platform and BioNavigator toolbox. A direct example of a software-assisted, screening-first positioning.
• Prozomix sells recombinant enzymes and proteins, serving screeners who want off-the-shelf panels rather than a custom project.
• Novonesis is the scale player in industrial and food enzymes. You will rarely out-fight it on volume; you can out-specialise it on a narrow reaction.

Map your business onto this set. Are you the next Prozomix (catalogue panels), the next Enzymaster (engineering projects), or a future acquisition target for a Johnson Matthey? Each answer implies a different capital need and a different exit, and the plan should say which one it is.

Funding Routes: SBA, SBIR, Innovate UK, SEIS

Biocatalysis startups rarely fit a single funding bucket. Pre-revenue research risk suits grants and equity; equipment and working capital suit debt; a signed pilot contract opens all of them. A sensible plan stages the raise.

US routes in the order they usually work

Non-dilutive research funding first. The Small Business Innovation Research and Small Business Technology Transfer programmes are run by agencies including NSF, NIH, the Department of Energy and USDA. A biocatalyst for greener pharmaceutical synthesis can reasonably be pitched to NSF or NIH; a biofuel or biochemical enzyme to DOE or USDA. Phase I awards typically sit in the low hundreds of thousands of dollars and fund proof of concept. Programme authorisation and award sizes change, so check the agency solicitation and the current reauthorisation status before you build a forecast around a specific figure.

SBA-backed debt second. A lender cannot underwrite an unproven enzyme, but it can underwrite a lab fit-out secured by equipment plus a contract. The 7(a) route works best once you hold a signed statement of work from a named customer, because the lender then sees a repayment source. Our plans for lab-based ventures include a debt service coverage table lenders recognise, with equipment depreciation treated honestly instead of ignored.

Equity third. Angel and seed investors in synthetic biology want a defensible technical asset: a patent filing, a proprietary enzyme library, or a screening platform with measured hit rates. Show the freedom-to-operate position early. A plan that names the three most relevant existing patent families, and explains why your enzymes sit outside them, answers the diligence question before it is asked.

UK routes

Innovate UK competitions, BBSRC and Engineering Biology funding streams, and university spin-out support are the first call for science-led companies. SEIS and EIS then cover private rounds: the company issues shares to investors who claim tax relief, which lowers their effective risk and makes a pre-revenue biotech raise easier. If you need help on eligibility, our Research + Content package includes the market analysis an advance assurance application asks for.

What a lender or grant reviewer scores

• Technical risk stated plainly: which reaction, what current conversion, what target, and the experiment that decides it
• A milestone budget tied to deliverables, not calendar months alone
• Named pilot customers or letters of intent, even if non-binding
• Scale-up path: who runs the fermentation at 10 litres, 100 litres and 1,000 litres, and at what cost
• An honest view of the cost of goods per kilogram of enzyme versus the incumbent catalyst

What It Costs to Stand Up the Lab and the Team

Avvale's modelling for a service-first biocatalysis company with a small wet lab puts seed capital between roughly $450,000 and $3.2 million (about £355,000 to £2.5 million). The low end assumes shared or incubator lab space and outsourced fermentation. The high end assumes your own 1,500 to 2,500 square foot BSL-1 laboratory, a pilot-scale fermentation suite, and a senior scientific hire. These are planning estimates, not quotes, and they move with local rents and equipment age.

Line items worth getting right

Two of these lines catch first-time founders out. Gene synthesis for a screening library of a few hundred variants adds up faster than expected, because each project needs fresh sequences. And outsourcing fermentation to a contract manufacturer can look cheap per batch but carries minimum run sizes and months-long queues, which belongs in your timeline risks.

Our bespoke business plan builds this table into a monthly cash model, so you can see the month the lab runs out of money under each hiring scenario instead of discovering it.

Equipment, Enzyme Panels and Supplier Names

Naming real suppliers in your plan shows a lender you have priced the build. The categories below are what a screening-and-engineering lab buys. Prices are typical new-equipment ranges; refurbished instruments can halve them.

Core equipment

• Liquid chromatography (HPLC / UHPLC), $40,000 to $120,000. The workhorse for measuring conversion and enantiomeric excess. Chiral columns add several thousand dollars each. Typical vendors: Agilent, Waters, Thermo Fisher.
• GC-MS, $50,000 to $130,000. For volatile products and flavour and fragrance work.
• Microplate reader, $15,000 to $45,000. High-throughput activity assays across 96 and 384-well plates. Vendors include Tecan, BioTek (now part of Agilent), and Molecular Devices.
• Liquid handler, $15,000 to $250,000. An Opentrons OT-2 or Flex sits at the low end for a startup; Hamilton and Tecan platforms sit at the high end and suit a lab running dozens of screens a week.
• Shaking incubators and thermocyclers, $8,000 to $20,000 each. Eppendorf and Thermo Fisher are the usual names.
• Benchtop bioreactors, $15,000 to $60,000 for 1 to 10 litre units. Sartorius and Eppendorf are common choices for protein expression runs.
• Ultra-low freezer and biosafety cabinet, $8,000 to $14,000 and $6,000 to $12,000. Needed for strain banks and sterile work.

Enzyme panels and DNA sources

Few startups begin by discovering enzymes from scratch. Most start from a commercial panel, then engineer. Prozomix sells recombinant enzymes in panels for screening. Codexis offers tailored enzymes for pharmaceutical manufacturing, per its pharma biocatalysis page. Enzymaster provides engineered enzymes and discovery services. For gene synthesis and library building, labs commonly use Twist Bioscience, Integrated DNA Technologies and GenScript. When you license an enzyme from any of these rather than develop it, your cost of goods and your freedom to operate both change, and the plan must say so.

Contract partners for scale-up

If you do not own pilot fermentation, name your contract development and manufacturing organisation (CDMO) or enzyme manufacturer, the batch size you can order, and the lead time. Almac and Johnson Matthey both operate biocatalysis-adjacent manufacturing, and the cphi-online directory lists a biocatalysts supplier directory useful for finding mid-sized contract producers. Buyers treat a named, reachable manufacturing partner as a sign you can actually deliver a kilogram.

Comparison: three ways to organise the same technology

Most successful companies start in column one or two to generate cash and evidence, then move toward column three. A plan that jumps straight to licensing without any revenue history asks an investor to fund science with no commercial proof.

Three Ways to Make Money From a Biocatalyst

The same enzyme can be monetised at three very different points. Choose one primary model for the first 24 months and name the second as an expansion stage.

1. Fee-for-service screening and engineering

A pharmaceutical process group has a ketone it needs converted into a single-mirror-image alcohol. You screen a panel of 96 to 384 enzymes, report conversion and selectivity, and if there is a hit you propose an engineering programme. The fee is time-and-materials or fixed-price per phase. This is the lowest-capital route and generates the case studies you need for credibility.

2. Enzyme and kit product sales

You manufacture or source an enzyme, package it, and sell it to labs and manufacturers by the gram or kilogram. Revenue depends on production cost per unit of activity. Because enzymes are sold on activity rather than weight, your plan should price per unit of activity and show how your cost of production falls with batch size.

3. Process licensing and long-term supply

You develop a route for a customer's molecule and agree a licence or a supply contract. The sitagliptin example sits here. Revenue is lumpy early and stable later. It requires patents, regulatory-grade documentation and, often, a customer willing to share a molecule with a small company, which takes trust and time.

A common hybrid works well: sell panels for cash, run engineering projects for evidence, and reserve the licensing conversation for the two or three projects that show a strong economic case. State that sequencing in the plan.

Unit Economics and Margin Ranges

Gross margins for mature enzyme and biocatalysis service companies commonly land between 55% and 75% in Avvale's models, with commodity-volume enzyme production at the low end of that band and custom engineering and licensing at the high end. Net margins are far lower early on, because R&D payroll is largely fixed. Expect operating losses through years one and two and a plan that shows the path to break-even, not a year-one profit.

Worked example: a four-person service lab, year two

This is an illustrative composite, not a forecast for your business. A company with a lead scientist, two research associates and one business developer sells three revenue types.

Direct costs, meaning consumables, gene synthesis, analytical time and subcontracted fermentation, run at about 34% of revenue, or $250,000. That leaves roughly $486,000 of gross profit, a 66% margin. Operating costs of about $610,000 (four salaries with on-costs, lab lease, insurance, patents and travel) produce an operating loss near $124,000. Add one more engineering milestone worth $180,000 in the same year and the business moves to a small profit. That sensitivity, one milestone deciding the year, is exactly what a lender needs to see and what a weak plan hides.

The levers that matter

• Hit rate. What share of screens find a usable enzyme? If 4 of 9 do, your phase-one pipeline is 4 candidate projects. Record it from day one; it is your best metric.
• Conversion from screen to engineering. Aim for a documented 25% to 40% in your forecast and justify it with pilot data.
• Utilisation of scientists. Billable project time against total time. Under 60% means you are underpricing or carrying idle capacity.
• Customer concentration. If one customer is more than 40% of revenue, say so and show the mitigation.
• Cost of goods per unit of enzyme activity (for product models). Fermentation titre, purification yield and storage stability drive it.

The financial tab in our industry-specific template structures these drivers as inputs, so changing hit rate or price updates the five-year model without rebuilding formulas.

Regulation: US, UK and EU

Biocatalysis is lightly regulated at the bench and heavily regulated at the point of sale. The rules that apply depend on three questions: is the organism genetically modified, is the enzyme used in food or pharmaceutical manufacturing, and where will you sell it?

United States

• Biosafety and recombinant DNA. Labs using recombinant organisms usually operate at Biosafety Level 1. Institutions that receive NIH funding follow the NIH Guidelines and an Institutional Biosafety Committee; a private lab typically mirrors that governance voluntarily or because customers and insurers expect it.
• TSCA for engineered microorganisms. Commercial use of an intergeneric microorganism can require a Microbial Commercial Activity Notice (MCAN) to the EPA before manufacture. Research and development exemptions exist, so confirm status before any commercial-scale production.
• Food enzymes. The FDA regulates enzyme preparations in food as food additives or through the GRAS notification route. Its published guidance on enzyme preparations sets out the information a notifier submits. GRAS notices for enzymes are public; the transglutaminase notice is one example of the expected dossier.
• Pharmaceutical manufacturing. If your enzyme is used to make an API, your customer's regulatory filing must justify it, and you may be audited as a critical supplier. ICH Q7 good manufacturing practice expectations for APIs flow down to your quality system.
• Worker safety. Enzyme dust is a respiratory sensitiser and occupational exposure limits are very low. OSHA hazard communication and a written exposure-control plan are standard.
• Business basics. State registration, EIN, sales-tax handling for kit sales, and export controls if you ship biological material abroad.

United Kingdom

• Genetically Modified Organisms (Contained Use) Regulations 2014. Administered by the Health and Safety Executive. You notify premises and risk-assess each activity by class; most enzyme work with safe host strains is Class 1.
• COSHH. The Control of Substances Hazardous to Health Regulations apply to enzymes as respiratory sensitisers and require assessment and control measures.
• UK REACH. Manufacturing or importing a substance above one tonne a year generally triggers registration. A startup selling kilogram quantities usually falls below that, but a growth plan should model the registration cost if it crosses the threshold.
• Food enzymes. Great Britain has been moving food enzymes onto a Food Standards Agency authorisation process. Confirm the current list status before promising a food customer a launch date.
• Company formation. Companies House registration; consider advance assurance from HMRC for SEIS and EIS before approaching investors.

European Union

Under the EU framework, all food enzymes, existing and new, must be safety-evaluated by EFSA and included in an EU Community list before they can be placed on the market, as described in the EFSA scientific guidance for food enzyme dossiers. EFSA also uses a Qualified Presumption of Safety approach for microorganisms used to produce food enzymes. Timelines for a dossier typically run to well over a year, so a food-ingredient plan aimed at Europe needs a long, funded regulatory workstream. Pharmaceutical-use enzymes follow customer-driven GMP rather than a standalone enzyme approval.

Compliance costs vary widely by use case. For a pharma-focused service lab, regulatory spend is mainly biosafety and quality-system setup. For a food-enzyme product, a dossier can consume a six-figure budget and the schedule. Put a line for it in your costs, whatever your market.

Mistakes That Sink Biocatalysis Plans

Most plans we review fail on commercial framing, not science. These are the five patterns we correct most often.

1. Quoting the $27.9 billion number for a $2 million business

Total enzyme market figures include detergents, feed and biofuel volumes you will not touch. Use the narrow pharma and fine-chemical pool, and show the bridge from market to share.

2. Treating the enzyme as the product when the customer buys a result

A process chemist wants a higher yield or a cleaner route. If your plan sells activity units without a measured improvement over the incumbent catalyst, it sells a commodity. Lead with the economics: yield gain, waste reduction, cycles of reuse.

3. Ignoring the cost of immobilisation and reuse

Enzymes can be inhibited by their substrate or product and are sensitive to temperature, pH and storage. Many commercial processes depend on immobilising and recycling the catalyst. If your cost model assumes single use and your competitor reuses the enzyme fifty times, you lose on price.

4. No freedom-to-operate analysis

Enzyme variants are patented, and so are the screening methods. An investor who finds an existing patent family you did not mention will discount the whole plan. A short, honest freedom-to-operate paragraph is a trust signal.

5. A hiring plan with no scientist who has scaled a process

Moving from a 1-litre flask to a 1,000-litre fermenter changes everything about enzyme expression and purification. Name the person, adviser or CDMO who has done it.

Questions Founders and Buyers Keep Asking

What is the difference between a biocatalyst and a chemical catalyst?

A biocatalyst is an enzyme or a whole cell that speeds up a reaction. Compared with metal catalysts, enzymes typically work under milder conditions, deliver high selectivity, and often avoid protecting-group steps, which is why they are attractive in pharmaceutical synthesis. The trade-off is sensitivity to heat, pH and inhibition, which is where process engineering earns its fee.

Do I need my own enzymes, or can I resell and engineer existing ones?

Most startups begin with licensed or commercially available enzymes, engineer them for a customer's reaction, and build proprietary variants over time. Your plan should state whether you own, license or merely use each enzyme, because that decides IP value and margin.

Whole-cell or isolated enzyme?

Whole cells are cheaper to prepare and handle cofactor regeneration naturally, but can bring side reactions and transport limits. Isolated enzymes give cleaner reactions and simpler regulation of the process, at higher production cost. Choose by reaction type and state the reason in the plan.

How long does a biocatalyst engineering project take?

A feasibility screen can finish in two to six weeks. Directed-evolution rounds typically take months, and the sitagliptin enzyme required many successive rounds to reach its more than 25,000-fold improvement. Build milestones around rounds of evolution and report improvement per round.

Is biocatalysis really greener?

Often, yes. Reactions run in water at moderate temperatures, produce fewer by-products and use fewer metals. The 2010 EPA award for the sitagliptin route recognised exactly this combination of yield and waste reduction. Quantify the improvement for your own reaction rather than asserting it.

Sample Plan Extract

This is how the opening of a biocatalysis plan reads when it is written for a lender. The company and numbers are a fictional composite.

What Is in the Template

The Avvale biocatalysis template gives you the structure above as a fill-in document, with prompts written for enzyme and biocatalyst businesses. Download it free, or pay $5 for the industry-specific version with the financial tabs.

• Executive Summary: the one-page pitch, with prompts for reaction, customer and economic gain
• Company Overview: legal structure, IP position and lab location
• Industry Analysis: market definition, share arithmetic and demand drivers
• Customer Analysis: process chemists, procurement and regulatory contacts
• Competitor Analysis: catalogue suppliers, engineering firms, large enzyme producers
• Technology and IP Plan: enzyme ownership, patents, freedom-to-operate
• Operations Plan: lab workflow, scale-up partners, quality system
• Management Team: scientific founders, advisers, key hires

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements. See our business plan writer service for how we work, and the related biotech business plan template if you plan a broader platform company.

Frequently Asked Questions